NCT03466736

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 165 (actual)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, including hippocampal volumes, functional connectivity, and APOE status. By realizing the aims of this pragmatic study, we hope to be able to offer more economical and efficient screening of potential participants for clinical trials, which would reduce participant burden and financial costs.

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	[18F]flutemetamol PET scan	Each subject will receive an amyloid PET scan with \[18F\]flutemetamol

Timeline

• Start date: 2018-09-01
• Primary completion: 2023-04-20
• Completion: 2023-04-20
• First posted: 2018-03-15
• Last updated: 2023-04-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study